GTS Securities’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-102,700
Closed -$12.2M 3155
2024
Q3
$12.2M Sell
102,700
-7,700
-7% -$1.03M 0.03% 426
2024
Q2
$15.8M Buy
110,400
+18,100
+20% +$2.4M 0.03% 319
2024
Q1
$11.9M Buy
92,300
+40,600
+79% +$4.83M 0.02% 437
2023
Q4
$5.35M Sell
51,700
-89,600
-63% -$8.86M 0.01% 952
2023
Q3
$12.8M Buy
+141,300
New +$12.4M 0.02% 495

Other funds holding NVO

GTS Securities's NVO Position: Q1 2026 in Review

GTS Securities sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 4,391 shares — an estimated $223K sold.

GTS Securities first reported a position in NVO in Q2 2023 and held it in 9 quarters. The position peaked at $3.6M in Q1 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • GTS Securities reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • GTS Securities sold 4,391 Novo Nordisk shares in Q1 2026, an estimated $223K.
  • GTS Securities first reported a position in Novo Nordisk in Q2 2023 and held it in 9 quarters.
  • GTS Securities's Novo Nordisk position peaked at $3.6M in Q1 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.